Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma
A case report
Jun Jin, BSb,∗, Jiahao Du, MSb, Yanwei Wu, MSb

Abstract

Rationale: Due to the anatomical and biological characteristics of nasopharyngeal carcinoma (NPC), radiotherapy is the standard treatment of choice. Recent advances in small molecule therapies targeting tumor angiogenesis also hold promise for the treatment of advanced NPC.

Patient concerns: The patient’s symptoms, including nasal obstruction, nasal bleeding, and headache, reappeared periodically and eventually became so severe that the patient’s vision became impaired. In January 2016, the patient presented with blurred vision, diplopia, language impairment, left temporal paralysis, and bilateral eyelid ptosis.

Diagnosis: Advanced NPC without metastasis in a 55-year-old man.

Interventions: The patient refused treatment with radiotherapy or chemotherapy and was treated with Chinese herbal medicines. Following a worsening of symptoms, the patient was subsequently treated with apatinib monotherapy (0.25 g, once daily).

Outcomes: Symptom improvement, including decreased nasal bleeding and headache, was observed after 1 week of apatinib treatment. After 100 days of treatment, the patient was nearly asymptomatic with stable disease and improved quality of life.

Lessons: For patients with advanced NPC who refuse standard radiotherapy and chemotherapy, apatinib monotherapy may be a suitable treatment option to improve symptoms and quality of life even in those with vascular endothelial growth factor receptor-negative tumors.

Abbreviations: ECOG = Eastern Cooperative Oncology Group, EGFR = epithelial growth factor receptor, MRI = magnetic resonance imaging, NPC = nasopharyngeal carcinoma, OS = overall survival, TKI = tyrosine kinase inhibitor, VEGF = vascular endothelial growth factor, VEGF-R2 = vascular endothelial growth factor receptor 2.

Keywords: apatinib, nasopharyngeal carcinoma, quality of life, symptoms

1. Introduction

Approximately 86,500 new cases of nasopharyngeal carcinoma (NPC) are found each year worldwide,[1] with most cases observed in Asia.[2] Because of the anatomical and biological characteristics of NPC, radiotherapy, especially intensity modulated radiotherapy, remains the treatment of choice.[3] For those patients with advanced NPC, comprehensive multidisciplinary treatment typically consists of radiotherapy plus chemothera- py.[3] However, the 5-year overall survival (OS) rates are as low as 28% for those with stage IV disease.[2] For those with distal metastasis, chemotherapy with prior or simultaneous palliative radiotherapy of the metastatic lesions is often employed.[2]

In addition to radiotherapy and chemotherapy, targeted drugs have been developed that inhibit tumor angiogenesis,[4] including cetuximab, gefitinib, erlotinib, sorafenib, nimotuzumab, and bevacizumab. However, no effective drug for the targeted therapy of NPC is available at present. Apatinib is another small molecule tyrosine kinase inhibitor (TKI) that is highly selective for vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis properties in vitro.[5] Apatinib has been used clinically for some advanced cancers, including advanced pancreatic liposarcoma,[6] gastric cancer,[7] liver cancer,[8] angiosarcoma,[9] nonsmall cell lung cancer,[10,11] and advanced lung adenocarcinoma,[12,13] with a favorable safety profile and demonstrated efficacy. However, the efficacy of apatinib in NPC is unknown.

Here, we report the outcomes of a patient with locally advanced NPC treated with apatinib mesylate, achieving favorable efficacy. This may be the first clinical case of advanced NPC in which symptoms were alleviated by apatinib monotherapy alone.
2. Case report

A male patient aged 55 years was admitted to the Dongguan People’s Hospital due to nasal obstruction and diagnosed with NPC in 2010. Although the patient refused radiotherapy, he was treated with Chinese medicinal herbs (150g/d; centipede, Tianlong, Herba Hedyotis, Centipeda minima, Agkistrodon spp., and Scutellaria barbata) prepared in beverage form. His symptoms, including nasal obstruction, nasal bleeding, and headache, reappeared periodically and eventually became so severe that the patient’s vision became impaired. In January 2016, the patient presented with blurred vision, diplopia, language impairment, left temporal paralysis, and bilateral eyelid ptosis (Fig. 1). In March 2016, magnetic resonance imaging (MRI) confirmed a diagnosis of NPC with involvement of the surrounding tissues, including the posterior nasal passage, bilateral Eustachian tubes, levator palate, circumflexus palate, orbital apex, nasal septum, wing sinus, basilar clivus, left cavernous sinus, and left temporal dura (Fig. 2). In addition, compression of the left temporal lobe was detected (Fig. 2). No metastasis was detected. Nasal biopsy and pathological examination showed nonkeratinizing cancer (undifferentiated), and immunohistochemistry analysis revealed that the tissues were negative for VEGFR-2. Radiotherapy was considered inadvisable because of the large size of the tumor and the potential for invading the base of the skull and the intracranial nerve. Instead, because the risk of possible damage to normal tissue by radiotherapy was likely to result in adverse consequences, palliative chemotherapy was recommended. However, the patient and his relatives refused chemotherapy. He was, therefore, treated with Huachansu tablets (2 tablets, thrice daily) for more than 2 months. On July 1, 2016, the patient was readmitted due to nasal obstruction, dyspnea, headache, left vision loss, right blurred vision, and diplopia. Physical examination showed apparent malnutrition, unstable walking, buccal respiration, the presence of black blood in the nose, complete ptosis of the left eyelid, vision loss in the left eye, incomplete ptosis of the right eyelid, blurred vision in the right eye.

Figure 1. Examination of the patient’s eye showed bilateral eyelid ptosis on July 2016 that was improved with apatinib treatment as shown in the images taken on September 2016 and April 2017.
eye, and diplopia (Fig. 1). The patient had an Eastern Cooperative Oncology Group (ECOG) score of 4.

Beginning July 4, 2016, the patient was treated with apatinib 0.25 mg, once daily. After 1 week following treatment initiation, nasal bleeding improved, massive necrotic tissues were shed, and nasal obstruction and headache were improved. After 2 weeks, the nasal bleeding stopped completely. After 1 month, the patient complained of mild nasal obstruction; however, nasal

Figure 2. Magnetic resonance imaging of the patient with nasopharyngeal carcinoma on March 2016 (top panels), September 2016 (middle panels), and April 2017 (bottom panels).
bleeding was absent, his right eyelid moved freely, and his vision was improved without diplopia. However, the symptoms of the left eye remained, and left temporal numbness and mild headache were noted. Moderate hand–foot syndrome was also observed. After treatment for 40 days, the patient did not report any headache, and his right vision had improved. In addition, his left eye was able to open, although incompletely, and left vision loss remained. After treatment for 2 months, left temporal numbness remained; his left eye opened incompletely with blurred vision and diplopia was noted. However, he was able to walk freely, the hand–foot syndrome was improved, his appetite was good, and urination and defecation were normal. After treatment for 70 days, left eyelid movement and left vision were improved; however, diplopia, nasal speech, and mild left temporal numbness remained. The patient’s spirit was improved to the extent that he could independently care for himself, and he had an improved ECOG score of 2. A second MRI on September 14, 2016 showed that the lesion was reduced significantly. After treatment for 100 days, bilateral eyelid movement was recovered and his right vision was clear (Fig. 1). Although mild left diplopia was noted, the patient could walk freely and had no hand skin lesions, and had normal appetite, urination, defecation, and blood pressure. The patient’s ECOG score further improved to 1. After treatment, MRI analysis showed the lesion gradually reduced over time. The most recent MRI analysis in April 2017 showed no further changes in left nasopharyngeal lesions and basilar tumor invasion, suggestive of disease stabilization. (The summary of symptom improvements was shown in Table 1.)

### Table 1

| Days after apatinib initiation | Symptoms |
|-------------------------------|----------|
| 1 wk                          | Reduced nasal bleeding |
|                               | Shedding of nasal necrotic tissues |
|                               | Improvements in nasal obstruction and headache |
| 2 wk                          | Nasal bleeding stopped |
| 1 mo                          | Free movement in the right eyelid |
|                               | Mildly impaired vision in the right eye |
| 40 d                          | Normal vision in the right eye |
|                               | Partial opening of the right eyelid |
| 70 d                          | Left diplopia |
|                               | Improved spirit |
| 100 d                         | Have the ability of living independence |
|                               | Clear vision in the right eye |
|                               | Mild diplopia in the left eye |

3. Discussion

Apatinib is a targeted therapy that inhibits tumor angiogenesis by targeting VEGFR-2. The drug may also inhibit some tyrosine kinases, such as platelet-derived growth factor receptor-b (PDGFR-b), c-Kit, Ret, and c-src, by suppressing the proliferation, migration, and microtubule formation of cancer cells. In clinical practice, apatinib has been used for treating advanced cancers, and has been investigated for the efficacy of apatinib in treating NPC. For the patient with advanced NPC presented in this case report, apatinib monotherapy alone was sufficient to ameliorate symptoms, leaving only moderate hand–foot syndrome.

In the targeted therapy of advanced NPC, inhibitors of epidermal growth factor receptor (EGFR) are commonly employed given that EGFR expression is often detected in most solid tumors, affecting the proliferation, invasion, and metastasis of cancer cells. High EGFR expression has been noted in about 80% to 90% of patients with NPC. Cao et al followed 127 patients with advanced NPC and found that the 5-year OS and 5-year disease-free survival (DFS) were better in patients with EGFR-negative tumors than in those positive for EGFR. Similarly, a meta-analysis by Ooft et al confirmed that EGFR overexpression predicts the OS and DFS of NPC patients. Thus, EGFR may represent a reliable biomarker for predicting the prognosis of NPC patients as well as an ideal target in the treatment of NPC. However, although EGFR monoclonal antibodies and TKIs are currently used for targeted therapy in NPC patients, results are inconsistent or inconclusive and further large-scale clinical trials are still needed. Cetuximab is an EGFR monoclonal antibody approved for the treatment of advanced head and neck squamous cell carcinoma. A large-scale phase III clinical trial conducted by Bonner et al showed that addition of cetuximab significantly improved the OS and DFS of patients with head and neck squamous cell carcinoma concurrently treated with chemotherapy as compared to chemotherapy alone. However, there is still controversy regarding the use of cetuximab for advanced NPC as traditional high-dose cisplatin-based chemotherapy was not included for comparison, and the findings were inconsistent with those reported in several other clinical trials. Nimotuzumab is a humanized monoclonal antibody against EGFR, and several studies have shown that it has favorable short-term efficacy and good tolerance in NPC patients. However, large-scale clinical trials are required to evaluate its long-term efficacy. Gefitinib is a small molecule TKI of epidermal growth factor. In Hong Kong, it has been used in the treatment of recurrent or metastatic NPC in phase II clinical trials. However, no improvements were detected, and the specific efficacy of gefitinib needs to be further studied.

Vascular endothelial growth factor (VEGF) is involved in tumor angiogenesis and is closely related to the growth, invasion, metastasis, and prognosis of a variety of cancers. Currently, 5 antiangiogenic drugs are available for the treatment of advanced NPC, including bevacizumab and 4 small molecule VEGFR-TKIs (sorafenib, sunitinib, pazopanib, and vandetanib). However, although these targeted drugs, especially when combined with standard chemotherapy, are shown to delay disease progression, some with satisfactory safety, no effective drug for the targeted therapy of NPC is yet available and further study is needed.

In a recent phase II trial comparing standard chemotherapy with standard chemotherapy plus bevacizumab that included 46 patients, bevacizumab combined with standard chemotherapy delayed disease progression with favorable safety. A phase III clinical trial is currently ongoing to investigate the efficacy of bevacizumab in the treatment of advanced NPC. Sorafenib is a multitarget drug with antitumor angiogenic activity and tyrosine kinase inhibition. In a phase II clinical trial, sorafenib showed good antiangiogenic effect with favorable tolerance in patients with metastatic NPC, and further investigation is ongoing. Sunitinib has dual antitumor activities that are similar to sorafenib. In patients with metastatic NPC who were nonresponsive to platinum-based chemotherapy or those previously treated with high dose radiation, severe hemorrhagic complications were observed. Thus, further analysis of the safety of sunitinib is warranted. Pazopatinib exerts antitumor effects by inhibiting angiogenesis as well as enzymes related to tumor growth.
growth. In a phase II clinical trial, pazotinib was used to treat Asian patients with advanced NPC, and results showed favorable safety and disease remission. Additional drugs targeting downstream molecules of the PI3K and mTOR-signaling pathways are being developed for targeted therapy of NPC. However, there is still no effective drug for the targeted therapy of NPC at present.

The apparent stabilization of advanced NPC and improvement in symptoms observed in the present case report was obtained with apatinib monotherapy alone after the patient had refused standard radiotherapy and chemotherapy. Given that the combination of antiangiogenic agents with radiotherapy may have synergistic effects, further studies combining apatinib with radiotherapy for advanced NPC are warranted. Moreover, enhanced targeted apatinib delivery via cyclic arginylglycylaspartic acid- and polyethylene glycol-modified liposomes may result in further antitumor activity with improved safety as shown through in vivo analysis.

With the exception of moderate hand–foot syndrome, the patient in the present case report did not experience any adverse events in response to the apatinib monotherapy. This favorable safety profile is similar to the findings of other previously published studies using this drug in patients with other cancer types with primary toxicities that included hypertension, hand–foot syndrome, proteinuria, and thrombocytopenia.

In conclusion, following apatinib treatment, the patient has survived with improved quality of life and few side effects. Although apatinib targets VEGFR-2, immunohistochemistry analysis showed that the tumor was negative for VEGFR-2. Thus, the effectiveness of apatinib might be ascribed to its multitarget activities, and other targets of apatinib should be further confirmed in future studies.

**Author contributions**

Conceptualization: Jun Jin.

Data curation: Yanwei Wu.

Formal analysis: Jiahao Du.

Writing – original draft: Jun Jin.

Writing – review & editing: Jun Jin.

**References**

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
[2] Zhang L, Chen QY, Liu H, et al. Emerging treatment options for nasopharyngeal carcinoma. Drug Des Dev Ther 2017;13:73–52.
[3] Xu C, Chen YP, Ma J. Clinical trials in nasopharyngeal carcinoma-past, present and future. Chin Clin Oncol 2016;5:20.
[4] Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, et al. Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies—a review. J Adv Res 2017;8:591–603.
[5] Peng QX, Han YW, Zhang YL, et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget 2017;8:32813–22.
[6] Han T, Luan Y, Xu Y, et al. Successful treatment of advanced pancreatic liposarcoma with apatinib: a case report and literature review. Cancer Biol Ther 2017;18:65–9.
[7] Zhang M, Deng W, Cao X, et al. Concurrent apatinib and local radiation therapy for advanced gastric cancer: a case report and review of the literature. Medicine (Baltimore) 2017;96:e6241.
[8] Kou P, Zhang Y, Shao W, et al. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget 2017;8:20510–5.
[9] Jia G, Hong L, Yang P. Successful treatment of angiosarcoma of the scalp with apatinib: a case report. Onco Targets Ther 2016;9:4989–92.
[10] Ding L, Li QJ, You KY, et al. The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature. Medicine (Baltimore) 2016;95:e3598.
[11] Song Z, Yu X, Lou G, et al. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther 2017;10:1821–5.
[12] Zeng DX, Wang CG, Huang JA, et al. Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. Onco Targets Ther 2017;10:4269–72.
[13] Zeng DX, Wang CG, Lei W, et al. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget 2017;8:66248–53.
[14] Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Dev Ther 2015;9:6075–81.
[15] Ding J, Chen X, Dai X, et al. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Sci Life Sci 2012;895–896:108–15.
[16] Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006;83:1005–16.
[17] Zhou Y, Tang P, Wang Y, et al. Advanced alveolar soft part sarcoma responds to apatinib. Oncotarget 2017;8:50314–22.
[18] Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666–72.
[19] Cao XJ, Hao JF, Yang XH, et al. Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med Oncol 2012;29:263–71.
[20] Ooft ML, Braunnus WW, Heus P, et al. Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis. Biomark Med 2015;9:997–1010.
[21] Bonner JA, Harari PM, Gutzat J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78.
[22] Li Y, Chen QY, Tang LQ, et al. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study. BMC Cancer 2017;17:567.
[23] He N, Si YF, Sun YJ. Effect of nimotuzumab combined with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Guangxi Med J 2013;35:834–7.
[24] Liao ZW, Zhou TC. Clinical study of concurrent radiotherapy and chemotherapy in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget 2017;8:1280–22.
[25] Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients of nasopharyngeal carcinoma. Invest New Drugs 2011;29:1123–30.
[26] Elser C, Siu LL, Winquist E, et al. Phase II study of sunitinib in patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Res Pract 2016;1:126–8.
[27] Liu W, He X. Advance in the relationship between nasopharyngeal carcinoma and vascular endothelial growth factor. Chin Foreign Med Res 2015;13:161–4.
[28] Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012;13:172–80.
[29] Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766–73.
[30] Hui EP, Lui VW, Wong CS, et al. Preliminary evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs 2011;29:1123–31.
[31] Hui EP, Ma BB, King AD, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011;22:1280–7.
[32] Lim WT, Ng QS, Ivey P, et al. A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 2011;17:5481–9.
[33] Chen J, Xu XH. Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma. Saudi Med J 2015;36:659–64.
[34] Song Z, Lin Y, Zhang X, et al. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects. Int J Nanomedicine 2017;12:1941–58.